# Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy

> **NCT05083117** · PHASE2 · WITHDRAWN · sponsor: **Sciwind Biosciences APAC CO Pty. Ltd.**

## Conditions studied

- COVID-19 Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** XW001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05083117
- **Lead sponsor:** Sciwind Biosciences APAC CO Pty. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-30
- **Primary completion:** 2022-03-10
- **Final completion:** 2022-04-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Difficulty in COVID-19 subject enrollment
- **Last updated:** 2023-08-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05083117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05083117, "Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05083117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*